Brain metastasis responding to gefitinib alone

被引：20

作者：

Poon, ANY

Ho, SSM

Yeo, W

Mok, TSK

机构：

[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China

[2] Chinese Univ Hong Kong, Dept Diagnost Imaging, Hong Kong, Hong Kong, Peoples R China

来源：

ONCOLOGY | 2004年 / 67卷 / 02期

关键词：

brain metastases; chemotherapy; lung cancer; metastases; radiotherapy; gefitinib;

D O I：

10.1159/000081005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A woman with stage IIIb non-small cell lung cancer (NSCLC) developed disease progression with brain metastases during chemotherapy. Due to unusual circumstances, the patient received gefitinib alone, without the use of corticosteroid treatment or radiotherapy. There was a dramatic clinical improvement within 1 week. Followup magnetic resonance imaging of the brain 1 month later showed decreases in both the size and number of brain metastases. The patient remains well 9 months after initiation of gefitinib. It is proposed that gefitinib may have a role in treatment of brain metastases from NSCLC. Copyright (C) 2004 S. Karger AG, Basel.

引用

收藏

页码：174 / 178

页数：5

相关论文

共 26 条

[1] Temozolomide for treating brain metastases [J].

Abrey, LE ;

Christodoulou, C .

SEMINARS IN ONCOLOGY, 2001, 28 (04) :34-42

[2] Phase II Randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases [J].

Antonadou, D ;

Paraskevaidis, M ;

Sarris, G ;

Coliarakis, N ;

Economou, I ;

Karageorgis, P ;

Throuvalas, N .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3644-3650

[3] Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease [J].

Ardizzoni, A ;

Hansen, H ;

Dombernowsky, P ;

Gamucci, T ;

Kaplan, S ;

Postmus, P ;

Giaccone, G ;

Schaefer, B ;

Wanders, J ;

Verweij, J .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2090-2096

[4] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[5]

Bianco C, 2002, CLIN CANCER RES, V8, P3250

[6] Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases [J].

Christodoulou, C ;

Bafaloukos, D ;

Kosmidis, P ;

Samantas, E ;

Bamias, A ;

Papakostas, P ;

Karabelis, A ;

Bacoyiannis, C ;

Skarlos, DV .

ANNALS OF ONCOLOGY, 2001, 12 (02) :249-254

[7] THE ROLE OF RADIATION-THERAPY IN THE TREATMENT OF BRAIN METASTASES [J].

COIA, LR .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (01) :229-238

[8] Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer [J].

Ebert, BL ;

Niemierko, E ;

Shaffer, K ;

Salgia, R .

ONCOLOGIST, 2003, 8 (01) :69-75

[9] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[10] SYSTEMIC COMBINATION CHEMOTHERAPY AS PRIMARY-TREATMENT OF BRAIN METASTASIS FROM LUNG-CANCER [J].

KANTARJIAN, H ;

FARHA, PAM ;

SPITZER, G ;

MURPHY, WK ;

VALDIVIESO, M .

SOUTHERN MEDICAL JOURNAL, 1984, 77 (04) :426-430